IL33 and melanoma: Results from such studies showed that local STING agonist administration reduces tumor size and/or increases survival for mice bearing melanoma, prostrate adenocarcinoma, gliomas, and head and neck squamous cell carcinomas (HNSCC).31,35,38,55,56 Melanoma studies also showed that activation of STING in tumor cells and DCs increases the infiltration of NK cells in the TME due to secretion of CXCL10 and CCL5 cytokines, whereas IL-33 secretion inhibited tumor growth.56 Notably, minimal CD8+ T cell activation was reported to accompany NK cell migration.56